Discover MabDesign
MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.

Access our network
Join the MabDesign network to take advantage of all the advantages and opportunities offered.

Develop your skills
Consult and register for our next training courses in order to acquire new expertise.

Explore our business services
The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.

Upcoming events
Add your title here
27
May.
May 27-28, 2026
Mabdesign Event
30
Jun.
30 June - 1 Juli 2026
Partner Event
30
Jun.
June, 30 - July 1, 2026
Mabdesign Event
08
Sep.
Septembre 8-9, 2026
Partner Event
22
Sep.
September 22-23 2026
Mabdesign Event
29
Sep.
29 September -1 October 2026
Partner Event
Our News

Multiple Sclerosis
5 May 2026
MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of multiple sclerosis (MS).

ZOOM ON - SMARTFREZZ
7 April 2026
SmartFreez is a biotech and engineering company
focused on the cryopreservation and freeze-thaw
challenges of biologics, from proteins to Cell &
Gene Therapies (CGTs).
Using Computational Fluid Dynamics (CFD)
modeling, SmartFreez designs reliable systems and
optimizes biologics preservation.

Bacteriophage Therapies
31 March 2026
MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and pipeline of cell therapies.
OUR BOARD OF DIRECTORS









































































































































































































































































































































































































